Login to Your Account



Symphogen Round Is 'Not Typical'; Funding Hard to Find

By Nuala Moran


Wednesday, January 19, 2011
LONDON – The $131 million raised by Symphogen A/S earlier this month – the the largest private financing ever for a European biotech – will be a boost for the sector in Denmark, but it does not mean the funding climate in Europe is improving.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription